A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma

Trial Profile

A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs TAK 573 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 22 Aug 2017 Planned initiation date changed from 25 Jul 2017 to 21 Sep 2017.
    • 17 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top